• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Decoy Therapeutics Inc.

    6/4/26 8:29:27 AM ET
    $DCOY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DCOY alert in real time by email
    DEFA14A 1 dcoy_2025_defa_14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

     

     

     

     

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

     

     

     

    Decoy Therapeutics Inc.

     

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

     

     

     

     

     

     

     

     

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    (1)

    Amount Previously Paid:

    (2)

    Form, Schedule or Registration Statement No.:

    (3)

    Filing Party:

    (4)

    Date Filed:

     

     

     

     

     

     


     

     

    img225855299_0.jpg

    Your Vote Counts! DECOY THERAPEUTICS INC. 2026 Annual Meeting Vote by July 13, 2026 11:59 PM ET Hextone, Inc. P.O. Box 9142 Farmingdale, NY 11735 1 OF 2 322,224 148,294 30# Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717 FLASHID-JOB# You invested in DECOY THERAPEUTICS INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on July 14, 2026. Get informed before you vote View the Form 10-K, Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 30, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.comControl # Smartphone users Point your camera here and vote without entering a control number Vote in Person at the Meeting* July 14, 2026 10:00 AM CDT Annual Meeting to be held virtually: To attend, you must register as a Beneficial Holder at the below URL: https://web.viewproxy.com/dcoy/2026*If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.

     


     

     

    img225855299_1.jpg

    Vote at www.ProxyVote.com FLASHID-JOB# Control # XXXX XXXX XXXX XXXX THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. DECOY THERAPEUTICS INC. 2026 Annual Meeting Vote by July 13, 2026 11:59 PM ET Voting Items 1. Election of Directors Nominees: 1 Patricia Gauthier 2 Jonathan Lieber 3 Frederick E. Pierce 2. A proposal to approve, on a non-binding basis, the compensation paid by the Company to its named executive officers as disclosed in the proxy statement. 3. A proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. NOTE: Such other business as may properly come before the meeting, and any adjournment or postponement thereof. Board Recommends For For For For For Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date. FLASHID-JOB# 1.00000 322,224 148,294

     


     

     

    img225855299_2.jpg

    Important Notice Regarding the Internet Availability of Proxy Materials for the Annual Meeting of Stockholders to be held virtually on July 14, 2026 at 10:00 a.m. CT. This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Proxy Statement and Annual Report are available at https://web.viewproxy.com/DCOY/2026If you want to receive a paper or email copy of these documents, you must request one by following the instructions below on or before July 2, 2026 to facilitate timely delivery. There is no charge to you for requesting a copy. Important information regarding the Internet availability of the Company’s proxy materials, instructions for accessing your proxy materials and voting online, and instructions for requesting paper or e-mail copies of your proxy materials are outlined in this Notice. NAME & ADDRESS HERE You must use the 11-digit Control Number located in the box to attend the Annual Meeting virtually, to vote via Internet, or to request proxy materials. CONTROL NUMBER STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING. To the Stockholders of Decoy Therapeutics Inc.: The 2026 Annual Meeting of Stockholders of Decoy Therapeutics Inc. will be held virtually on July 14, 2026 at 10:00 a.m. CT. As a Registered Holder, you may attend and vote your shares at the virtual Annual Meeting by registering at https://web.viewproxy.com/DCOY/2026 and using the Control Number above. Your registration must be received by 11:59 p.m. on July 12, 2026. On the day of the Annual Meeting, if you have properly registered, you may log in using the link you received via email in your registration confirmation and follow the instructions to vote your shares. Please have your Control Number with you during the Annual Meeting in order to vote. Further instructions on how to attend and vote during the Annual Meeting are contained in the Proxy Statement in the section titled “Questions and Answers About These Proxy Materials and Voting – How can I attend the Annual Meeting?” and “Questions and Answers About These Proxy Materials and Voting – How do I vote?” The Board recommends a vote “FOR” Proposals 1, 2, and 3. 1. Election of Directors: 01. Patricia Gauthier 02. Jonathan Lieber 03. Frederick E. Pierce 3. A proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. 2. A proposal to approve, on a non-binding basis, the compensation paid by the Company to its named executive officers as disclosed in the proxy statement. NOTE: To conduct any other business properly brought before the Annual Meeting or any adjournment, postponement, or rescheduling thereof.

     


     

     

    img225855299_3.jpg

    The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet. Materials for this Annual Meeting and future meetings may be requested by one of the following methods: Internet Go to https://web.viewproxy.com/DCOY/2026. Have the 11-digit Control Number available when you access the website and follow the instructions. Telephone Call 1-877-777-2857 Toll Free E-Mail By e-mail at: requests@viewproxy.com * If requesting material by e-mail, please send a blank e-mail with the company name and your 11-digit Control Number in the subject line. No other requests, instructions, or other inquiries should be included within this email request. CONTROL NUMBER VOTING METHODS Via Internet prior to the Annual Meeting: Go to http://www.AALvote.com/DCOY. Have your 11-digit Control Number available and follow the prompts. Your electronic vote prior to the Annual Meeting authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned a proxy card. Via Internet during the Annual Meeting: Go to http://www.AALvote.com/DCOY Have your 11-digit Control Number available and follow the prompts.

     


    Get the next $DCOY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DCOY

    DatePrice TargetRatingAnalyst
    1/23/2026$2.50Buy
    Ladenburg Thalmann
    More analyst ratings

    $DCOY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Decoy Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Decoy Therapeutics with a rating of Buy and set a new price target of $2.50

    1/23/26 8:18:55 AM ET
    $DCOY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DCOY
    SEC Filings

    View All

    SEC Form EFFECT filed by Decoy Therapeutics Inc.

    EFFECT - Decoy Therapeutics Inc. (0001615219) (Filer)

    7/20/26 12:15:15 AM ET
    $DCOY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Decoy Therapeutics Inc.

    424B3 - Decoy Therapeutics Inc. (0001615219) (Filer)

    7/17/26 5:08:25 PM ET
    $DCOY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Decoy Therapeutics Inc.

    8-K - Decoy Therapeutics Inc. (0001615219) (Filer)

    7/15/26 5:14:18 PM ET
    $DCOY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DCOY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors

    CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held July 14, 2026 Ms. Gauther will serve with the Company's other two Class II directors, Rick Pierce and Jon Lieber, each of whom were re-elected at the annual meeting. "Patricia has spent her career making sure important medicines reach the peopl

    7/15/26 9:24:00 AM ET
    $DCOY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

    DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. Universe Pharmaceuticals (NASDAQ:UPC) announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.7

    6/29/26 9:50:32 AM ET
    $UPC
    $DCOY
    $VRDN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

    HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for a private investment in public equity financing (the "PIPE"), which is expected to provide approximately $3.5 million in gross proceeds at closing, before deducting placement agent's fees and other financing expenses payable by the Company. The Company intends to use the net proc

    6/26/26 8:11:00 PM ET
    $DCOY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DCOY
    Leadership Updates

    Live Leadership Updates

    View All

    Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board

    Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical developmentNEW YORK and CAMBRIDGE, Mass., May 26, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a clinical-stage biotechnology company pioneering a new category of antivirals, today announced the appointment of Brad L. Pentelute, Ph.D., Professor of Chemistry at the Massachusetts Institute of Technology, as Chair of its Scientific Advisory Board (SAB). Dr. Pentelute is an original co-founder of Decoy and has served as a Technology Advisor since the company's inception. He is widely recognized for his foundational contributions to peptide synthesis and protein engi

    5/26/26 8:15:00 AM ET
    $DCOY
    Biotechnology: Pharmaceutical Preparations
    Health Care